Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | Are we moving away from transplantation for the treatment of myeloma?

Fredrik Schjesvold • 10 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Bortezomib CAR-T Ciltacabtagene autoleucel Daratumumab Dexamethasone Lenalidomide
CARTITUDE-6 DETERMINATION

Fredrik Hellem Schjesvold, MD, PhD, Oslo University Hospital, Oslo, Norway, shares some insights into the future treatment landscape of multiple myeloma, drawing focus on the role of transplantation and whether treatment will move away from this approach. Dr Schjesvold highlights the DETERMINATION trial (NCT01208662) and also mentions upcoming trials investigating this, as well as the role of bispecifics in the future of myeloma therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Honoraria/advisory boards Sanofi, Amgen, Janssen

More from Fredrik Schjesvold

Phase II TALTEC: bispecific T-cell redirectors in frontline therapy for transplant-eligible myeloma 1:36
Phase II TALTEC: bispecific T-cell redirectors in frontline therapy for transplant-eligible myeloma
Fredrik Schjesvold • 17 Sep 2025
How do outcomes differ when myeloma treatment begins at MRD positivity versus symptomatic relapse? 2:41
How do outcomes differ when myeloma treatment begins at MRD positivity versus symptomatic relapse?
Fredrik Schjesvold • 17 Sep 2025
The potential impact of CAR-T therapies on the future role of HSCT in multiple myeloma 2:18
The potential impact of CAR-T therapies on the future role of HSCT in multiple myeloma
Fredrik Schjesvold • 14 Jun 2025
The REST trial: isatuximab, bortezomib, lenalidomide, and dexamethasone in transplant-ineligible MM 1:43
The REST trial: isatuximab, bortezomib, lenalidomide, and dexamethasone in transplant-ineligible MM
Fredrik Schjesvold • 14 Jun 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals